MA37742B1 - Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments - Google Patents

Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments

Info

Publication number
MA37742B1
MA37742B1 MA37742A MA37742A MA37742B1 MA 37742 B1 MA37742 B1 MA 37742B1 MA 37742 A MA37742 A MA 37742A MA 37742 A MA37742 A MA 37742A MA 37742 B1 MA37742 B1 MA 37742B1
Authority
MA
Morocco
Prior art keywords
preparation
medicaments
tetraene
derivatives
manufacture
Prior art date
Application number
MA37742A
Other languages
English (en)
Other versions
MA37742A1 (fr
Inventor
Ulrich Bothe
Naomi Barak
Matthias Busemann
Oliver Martin Fischer
Andrea Rotgeri
Tobias Marquardt
Christian Stegmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48748225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37742(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA37742A1 publication Critical patent/MA37742A1/fr
Publication of MA37742B1 publication Critical patent/MA37742B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des inhibiteurs de akr1c3 et des procédés pour les préparer, ainsi que leur utilisation pour traiter et/ou prévenir des maladies et pour fabriquer des médicaments destinés à traiter et/ou à prévenir des maladies, en particulier les troubles hémorragiques et l'endométriose.
MA37742A 2012-07-10 2015-01-07 Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments MA37742B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012211970 2012-07-10
PCT/EP2013/064257 WO2014009274A1 (fr) 2012-07-10 2013-07-05 Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments

Publications (2)

Publication Number Publication Date
MA37742A1 MA37742A1 (fr) 2016-05-31
MA37742B1 true MA37742B1 (fr) 2016-12-30

Family

ID=48748225

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37742A MA37742B1 (fr) 2012-07-10 2015-01-07 Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments

Country Status (28)

Country Link
US (1) US9512169B2 (fr)
EP (1) EP2872524B1 (fr)
JP (1) JP6196302B2 (fr)
KR (1) KR20150036319A (fr)
CN (1) CN104428309B (fr)
AP (1) AP2014008179A0 (fr)
AR (1) AR092025A1 (fr)
AU (1) AU2013289344A1 (fr)
BR (1) BR112015000443A2 (fr)
CA (1) CA2878485A1 (fr)
CL (1) CL2015000039A1 (fr)
CO (1) CO7160008A2 (fr)
CR (1) CR20150007A (fr)
DO (1) DOP2015000005A (fr)
EA (1) EA201500112A1 (fr)
EC (1) ECSP15000868A (fr)
ES (1) ES2603258T3 (fr)
HK (1) HK1205743A1 (fr)
IL (1) IL236581A0 (fr)
MA (1) MA37742B1 (fr)
MX (1) MX2015000347A (fr)
PE (1) PE20150353A1 (fr)
PH (1) PH12015500062A1 (fr)
TN (1) TN2015000007A1 (fr)
TW (1) TW201402596A (fr)
UY (1) UY34899A (fr)
WO (1) WO2014009274A1 (fr)
ZA (1) ZA201500920B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014220800A1 (en) * 2013-02-21 2015-08-27 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1 C3)
US20170260226A1 (en) * 2014-09-11 2017-09-14 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors
US10167293B2 (en) 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
EP3269373A1 (fr) 2016-07-11 2018-01-17 Bayer Pharma Aktiengesellschaft Formes posologiques orales à faible dosage d'un inhibiteur de akr1c3 pour le traitement des maladies
US20200085791A1 (en) 2016-12-19 2020-03-19 Bayer Pharma Aktiengesellschaft [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
CA3047191A1 (fr) 2016-12-19 2018-06-28 Bayer Pharma Aktiengesellschaft [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
TW201825478A (zh) 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
EP3421483A1 (fr) 2017-06-29 2019-01-02 Bayer Pharma Aktiengesellschaft Nouveaux dérivés 17-beta-hétéroaryle des stéroïdes comme inhibiteurs de akr1c3
CN110693892A (zh) * 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
CN110272465A (zh) * 2019-07-15 2019-09-24 成都贝诺科成生物科技有限公司 阿比特龙衍生物、其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2742331B2 (ja) * 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
PT973790E (pt) 1997-04-07 2003-10-31 Wyeth Corp Estra-5, 7-dienos com actividade estrogenica
AU2707999A (en) * 1998-03-11 1999-09-27 Endorecherche Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
JP2002522380A (ja) * 1998-08-07 2002-07-23 アンドルシェルシュ・インコーポレイテッド タイプ３３α−ヒドロキシステロイドデヒドロゲナーゼの阻害
AU2001248849A1 (en) * 2000-04-24 2001-11-07 Kyowa Hakko Kogyo Co. Ltd. Estra-1,3,5(10)-triene derivatives
CA2558014A1 (fr) 2004-03-12 2005-09-29 Entremed, Inc. Agents anti-angiogeniques
EP1990335A4 (fr) 2006-03-02 2009-11-11 Astellas Pharma Inc Inhibiteur de la 17 beta hsd de type 5
CA2671075A1 (fr) 2006-11-30 2008-06-05 Solvay Pharmaceuticals Gmbh Derives oestatrienes substitues en tant qu'inhibiteurs de la 17beta hsd
RU2009123133A (ru) 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
JP5251876B2 (ja) 2007-07-24 2013-07-31 アステラス製薬株式会社 ベンズイミダゾール誘導体
DE102011083725A1 (de) * 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
WO2014009274A1 (fr) 2014-01-16
ZA201500920B (en) 2017-01-25
HK1205743A1 (en) 2015-12-24
EP2872524B1 (fr) 2016-08-24
EP2872524A1 (fr) 2015-05-20
BR112015000443A2 (pt) 2017-06-27
IL236581A0 (en) 2015-02-26
PH12015500062A1 (en) 2015-03-02
CL2015000039A1 (es) 2015-03-27
AP2014008179A0 (en) 2014-12-31
TN2015000007A1 (en) 2016-06-29
MA37742A1 (fr) 2016-05-31
CO7160008A2 (es) 2015-01-15
JP6196302B2 (ja) 2017-09-13
UY34899A (es) 2014-02-28
ES2603258T3 (es) 2017-02-24
PE20150353A1 (es) 2015-03-28
US20150210734A1 (en) 2015-07-30
AU2013289344A1 (en) 2015-02-05
CA2878485A1 (fr) 2014-01-16
TW201402596A (zh) 2014-01-16
MX2015000347A (es) 2015-04-14
ECSP15000868A (es) 2016-01-29
US9512169B2 (en) 2016-12-06
AR092025A1 (es) 2015-03-18
JP2015522050A (ja) 2015-08-03
KR20150036319A (ko) 2015-04-07
CN104428309B (zh) 2016-09-14
EA201500112A1 (ru) 2015-07-30
DOP2015000005A (es) 2015-02-15
CN104428309A (zh) 2015-03-18
CR20150007A (es) 2015-03-13

Similar Documents

Publication Publication Date Title
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA42376A (fr) Dérivés d'oxopyridine substitués
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
BR112013008140A8 (pt) "compostos imidazotriazinona".
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
CA2883210C (fr) Composes aza bicycliques utilises comme agonistes du recepteur muscarinique m1
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA30914B1 (fr) Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques.
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA35638B1 (fr) 2-thiopyrimidinones
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives